(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The cheap health insurance promoted by Trump officials has this catch - 2Artemis II astronauts arrive at Florida launch site for first moon trip in 53 years
- 3Figure out How to Plan for Your Web-based Degree monetarily
- 4Radiated Tortoise Faces Rapid Decline in Madagascar
- 5Weeks-Long Australian LNG Outage Will Further Tighten Supply
- At least 11 killed in South Africa mass shooting
- Famous Places to get-away for Americans
- Only 30% of young people in Israel optimistic about future, Aluma survey reveals
- Germany's Bundestag extends two armed forces missions abroad
- Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- Lilly, Novo lock horns in India's obesity drug race
- 10 High priority Contraptions for Tech Aficionados
- Worldwide Objections Ideal For A Golf Outing
- These four astronauts could soon travel farther from Earth than anyone has gone before
